Demand Creation Officer

221

RIGHT TO CARE

Position: Demand Creation Officer x 1

Location: Maseru

Contract type: Fixed-Term until 31 May 2024

Minimum Required Qualifications and Experience

• Diploma in General Nursing and Midwifery

• Desirable bachelor’s degree in nursing

• Post-graduate diploma in HIV/AIDS management

• Experience in management of records and files

• Basic understanding of HIV & AIDS and other chronic conditions

• Active mobilization of patients through health talks.

• Experience in a public health setting desirable

• Experience working with PEPFAR/USAID Implementing partners

TECHNICAL AND BEHAVIOURAL COMPETENCIES

• Knowledge of the Lesotho public healthcare environment

• Maintain patient confidentiality

• Be consistent and reliable in reporting to all stakeholders.

• Computer literate and willing to learn and use any other software systems the company requires in the execution of the CDU

process

KEY PERFORMANCE AREAS

• Ensure patients understand the decentralised drug distribution system and benefits to them.

• Ensure patients understand the process and criteria for accessing the decentralised drug distribution program.

• Ensure that patients identified as eligible by clinicians receive their appointment dates for next collection.

• Source and sort potential patient files at each facility and channel towards clinicians.

• Support consenting patients to use the decentralised drug distribution program.

• Ensure patients understand the pick-up cycle.

• Handle additional patient queries.

• Escalate problems through appropriate channels.

• Liaise with site staff and call centre in tracking and following up with enrolled patients.

• Support the process of co-ordinating and preparing scripts that need to be sent for capturing.

• Manage rejected scripts on behalf of CDU and liaise with facilities and call centre to provide reasons for rejection.

• Communicating with automated sites, CDU and other relevant partners to ensure ensure patients are serviced optimally.

Deadline: 21st February 2024

Contact Email: [email protected]

Comments